

EPIX MEDICAL INC  
Form 8-K  
May 28, 2003

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

## FORM 8-K

### CURRENT REPORT

Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

---

Date of Report (Date of earliest event reported): **May 27, 2003**

## **EPIX Medical, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of incorporation)

**000-21863**  
(Commission File Number)

**04-3030815**  
(IRS Employer Identification No.)

**71 Rogers Street**  
**Cambridge, Massachusetts 02142**

Edgar Filing: EPIX MEDICAL INC - Form 8-K

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(617) 250-6000**

---

**Item 5. Other Events.**

On May 27, 2003, Epix Medical, Inc. and Schering AG issued a press release announcing that they have formed a broad alliance for the discovery, development and commercialization of novel molecularly-targeted contrast agents for magnetic resonance imaging (MRI). The alliance is comprised of two areas of collaboration: 1) an exclusive development and commercialization partnership for EP-2104R, EPIX product candidate for the detection of thrombus (blood clots); and 2) an exclusive research partnership to discover novel compounds for MRI. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

**Item 7. Financial Statements and Exhibits.**

(c) The following exhibits are furnished with this report:

| <b>Exhibit Number</b> | <b>Description</b>                |
|-----------------------|-----------------------------------|
| 99.1                  | Press Release dated May 27, 2003. |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EPIX Medical, Inc.  
(Registrant)

Date: May 27, 2003

/s/

Peyton J. Marshall  
Peyton J. Marshall  
Senior Vice-President,  
*Finance and Administration,*  
*Chief Financial Officer*